
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is transitioning from a catalyst-driven biotech into a diversified, cash-generating platform, with Zanidatamab’s U.S. FDA approval for 1L HER2+ GEA unlocking a $250M milestone, expanding royalties, and supporting a broad label that management and collaborators believe can anchor blockbuster economics. The company’s raised FY26 guidance to $337M-$351M of revenue and $176M-$190M of adjusted EBITDA, together with $514.3M of cash and recurring Yupelri cash flow, suggests improving operating leverage and a stronger self-funding model. Additional upside comes from capital-efficient partnerships like Roche for ZW209, plus internally developed assets such as ZW191 and partnered programs like pasritamig, which broaden value creation while limiting Zymeworks-funded R&D risk.
Bears say
Zymeworks is viewed negatively because, as a clinical-stage biotechnology company, it faces multiple layers of risk at once: clinical failure, regulatory setbacks, commercialization challenges, and broader industry volatility. Its reliance on capital-intensive development creates meaningful funding risk, since the capital-raising environment can shift and necessary financing may not be readily available to complete its clinical programs. The company is also exposed to concentration risk around zanidatamab, alongside liquidity, partnership, competitive, legal, intellectual property, macroeconomic, and geopolitical risks that can materially impair long-term value creation.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Zymeworks Inc (ZYME) Forecast
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares